MCID: OVR029
MIFTS: 64

Ovarian Hyperstimulation Syndrome

Categories: Genetic diseases, Reproductive diseases, Rare diseases

Aliases & Classifications for Ovarian Hyperstimulation Syndrome

MalaCards integrated aliases for Ovarian Hyperstimulation Syndrome:

Name: Ovarian Hyperstimulation Syndrome 53 12 55 71 36 28 13 51 41 14 69
Ohss 53 55 71
Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous 53
Secondary Meig's Syndrome 12

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant

Miscellaneous:
symptoms occur only during pregnancy (usual onset after 6 weeks gestation)
major fluid shifts may occur in severe cases


HPO:

31
ovarian hyperstimulation syndrome:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 608115
Disease Ontology 12 DOID:5425
MeSH 41 D016471
SNOMED-CT 64 129635004
Orphanet 55 ORPHA64739
MESH via Orphanet 42 D016471
UMLS via Orphanet 70 C0085083
ICD10 via Orphanet 33 N98.1
MedGen 39 C0085083
KEGG 36 H01039
UMLS 69 C0085083

Summaries for Ovarian Hyperstimulation Syndrome

UniProtKB/Swiss-Prot : 71 Ovarian hyperstimulation syndrome: Disorder which occurs either spontaneously or most often as an iatrogenic complication of ovarian stimulation treatments for in vitro fertilization. The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargement and capillary leak with fluid sequestration. Pathologic features of this syndrome include the presence of multiple serous and hemorrhagic follicular cysts lined by luteinized cells, a condition called hyperreactio luteinalis.

MalaCards based summary : Ovarian Hyperstimulation Syndrome, also known as ohss, is related to hydrops, lactic acidosis, and sideroblastic anemia and polycystic ovary syndrome, and has symptoms including abdominal pain, nausea and ascites. An important gene associated with Ovarian Hyperstimulation Syndrome is FSHR (Follicle Stimulating Hormone Receptor), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and Development Endothelin-1/EDNRA signaling. The drugs Dopamine and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and pituitary, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 72 Ovarian hyperstimulation syndrome (OHSS) is a medical condition affecting the ovaries of some women who... more...

Description from OMIM: 608115

Related Diseases for Ovarian Hyperstimulation Syndrome

Diseases related to Ovarian Hyperstimulation Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Related Disease Score Top Affiliating Genes
1 hydrops, lactic acidosis, and sideroblastic anemia 30.5 ALB VEGFA
2 polycystic ovary syndrome 30.0 CYP19A1 FSHR GNRH1
3 anuria 29.9 ALB REN
4 endometriosis 29.4 CYP19A1 GNRH1 VEGFA
5 infertility 29.2 CYP19A1 FSHR GNRH1 LHCGR
6 ovarian disease 28.6 AMH CGA CYP19A1 FSHR GNRH1
7 endotheliitis 10.7
8 complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy 10.5
9 thrombosis 10.5
10 acroosteolysis 10.4 ALB VEGFA
11 background diabetic retinopathy 10.4 ALB VEGFA
12 angiokeratoma circumscriptum 10.4 KDR VEGFA
13 hydrocele 10.4 CGA VEGFA
14 hypertensive nephropathy 10.4 ALB VEGFA
15 gastric lymphoma 10.4 ALB VEGFA
16 skin hemangioma 10.4 KDR VEGFA
17 capillary hemangioma 10.4 KDR VEGFA
18 radiation proctitis 10.4 KDR VEGFA
19 epithelioid hemangioendothelioma 10.4 KDR VEGFA
20 kuhnt-junius degeneration 10.4 KDR VEGFA
21 nodular prostate 10.4 GNRH1 KDR
22 acute hemorrhagic leukoencephalitis 10.4 KDR VEGFA
23 angiomatous meningioma 10.3 KDR VEGFA
24 leydig cell hypoplasia 10.3 CGA LHCGR
25 retinal vascular occlusion 10.3 F5 VEGFA
26 coats disease 10.3 KDR VEGFA
27 ovarian serous cystadenocarcinoma 10.3 FSHR VEGFA
28 leukostasis 10.3 KDR VEGFA
29 priapism 10.3 F5 GNRH1
30 freemartinism 10.3 AMH GNRH1
31 lymphangioma 10.2 KDR VEGFA
32 central retinal vein occlusion 10.2 F5 VEGFA
33 adenoma 10.2
34 benign essential hypertension 10.2 ALB REN
35 kidney papillary necrosis 10.2 ALB REN
36 peritonitis 10.2
37 orthostatic proteinuria 10.2 ALB REN
38 retinal vascular disease 10.2 ALB KDR VEGFA
39 microvascular complications of diabetes 5 10.2 ALB KDR VEGFA
40 severe pre-eclampsia 10.2 ALB F5 VEGFA
41 ectopic pregnancy 10.2
42 hypothyroidism 10.2
43 thrombophilia 10.2
44 pituitary adenoma 10.2
45 thrombophilia due to thrombin defect 10.1
46 cerebritis 10.1
47 oocyte maturation defect 1 10.1 CGA CYP19A1
48 gonadal disease 10.1 AMH FSHR GNRH1
49 penis agenesis 10.1 CGA GNRH1 LHCGR
50 amenorrhea 10.1 FSHR GNRH1 LHCGR

Graphical network of the top 20 diseases related to Ovarian Hyperstimulation Syndrome:



Diseases related to Ovarian Hyperstimulation Syndrome

Symptoms & Phenotypes for Ovarian Hyperstimulation Syndrome

Symptoms via clinical synopsis from OMIM:

53
Abdomen:
abdominal pain
ascites

Genitourinary Internal Genitalia Female:
enlarged multilocular ovaries
pathology shows multiple serous and hemorrhagic follicular cysts lined by luteinized cells ('hyperreactio luteinalis')
ovaries return to normal size after delivery

Abdomen Gastroin testinal:
nausea


Clinical features from OMIM:

608115

Human phenotypes related to Ovarian Hyperstimulation Syndrome:

55 31 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abdominal pain 55 31 hallmark (90%) Very frequent (99-80%) HP:0002027
2 nausea 55 31 hallmark (90%) Very frequent (99-80%) HP:0002018
3 ascites 55 31 hallmark (90%) Very frequent (99-80%) HP:0001541
4 increased circulating gonadotropin level 55 31 hallmark (90%) Very frequent (99-80%) HP:0000837
5 enlarged polycystic ovaries 55 31 hallmark (90%) Very frequent (99-80%) HP:0008675
6 abdominal distention 55 31 hallmark (90%) Very frequent (99-80%) HP:0003270
7 increased serum testosterone level 55 31 hallmark (90%) Very frequent (99-80%) HP:0030088
8 hypovolemia 55 31 occasional (7.5%) Occasional (29-5%) HP:0011106
9 pleural effusion 55 31 frequent (33%) Frequent (79-30%) HP:0002202
10 hirsutism 55 31 hallmark (90%) Very frequent (99-80%) HP:0001007
11 peripheral edema 55 31 occasional (7.5%) Occasional (29-5%) HP:0012398
12 hemorrhagic ovarian cyst 55 31 frequent (33%) Frequent (79-30%) HP:0012886
13 pulmonary edema 55 31 occasional (7.5%) Occasional (29-5%) HP:0100598
14 generalized edema 55 31 occasional (7.5%) Occasional (29-5%) HP:0007430
15 capillary leak 55 31 hallmark (90%) Very frequent (99-80%) HP:0030005
16 nausea and vomiting 55 Very frequent (99-80%)
17 abnormality of the genitourinary system 31 HP:0000119
18 ovarian cyst 55 Frequent (79-30%)

UMLS symptoms related to Ovarian Hyperstimulation Syndrome:


nausea, abdominal pain

MGI Mouse Phenotypes related to Ovarian Hyperstimulation Syndrome:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.23 CGA GNRH1 CYP19A1 ALB AMH F5
2 growth/size/body region MP:0005378 10.19 FSHR CGA CYP19A1 F5 CDH5 LHCGR
3 endocrine/exocrine gland MP:0005379 10.16 FSHR CGA CYP19A1 ALB AMH CDH5
4 cardiovascular system MP:0005385 10.13 CDH5 FSHR CYP19A1 F5 LHCGR REN
5 hematopoietic system MP:0005397 10.08 CDH5 FSHR CYP19A1 VEGFA LHCGR GNRH1
6 immune system MP:0005387 10.03 CDH5 FSHR CYP19A1 KDR VEGFA LHCGR
7 liver/biliary system MP:0005370 9.97 GNRH1 CYP19A1 ALB F5 CDH5 LHCGR
8 integument MP:0010771 9.95 CDH5 FSHR CYP19A1 F5 VEGFA GNRH1
9 nervous system MP:0003631 9.91 FSHR CGA CYP19A1 F5 LHCGR GNRH1
10 normal MP:0002873 9.76 CYP19A1 ALB CDH5 LHCGR GNRH1 REN
11 neoplasm MP:0002006 9.72 FSHR ALB AMH VEGFA GNRH1
12 renal/urinary system MP:0005367 9.43 ALB CYP19A1 VEGFA LHCGR GNRH1 REN
13 reproductive system MP:0005389 9.28 FSHR CGA GNRH1 CYP19A1 AMH CDH5

Drugs & Therapeutics for Ovarian Hyperstimulation Syndrome

Drugs for Ovarian Hyperstimulation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Progesterone Approved, Vet_approved Phase 4,Phase 3 57-83-0 5994
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
4
Metformin Approved Phase 4 657-24-9 4091 14219
5
Cabergoline Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 81409-90-7 54746
6
Leuprolide Approved, Investigational Phase 4,Phase 3 53714-56-0 657181 3911
7
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112809-51-5 3902
8
Cetrorelix Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 120287-85-6 25074887 16129715
9
Ganirelix Approved Phase 4,Phase 3,Phase 2 124904-93-4, 123246-29-7 25081094
10
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
11
Buserelin Approved, Investigational Phase 4 57982-77-1
12
Nafarelin Approved Phase 4 76932-56-4 25077649 16129618
13
Menotropins Approved Phase 4,Phase 3 9002-68-0, 61489-71-2 5360545
14
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
15
Norgestrel Approved Phase 4 6533-00-2 13109
16
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
17
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 77-92-9 311
18
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
19
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
21
Enclomiphene Investigational Phase 4,Phase 2,Phase 3,Phase 1 15690-57-0
22 Progestins Phase 4,Phase 3,Phase 2
23 Deslorelin Phase 4,Phase 3,Phase 2,Early Phase 1
24 Estradiol valerate Phase 4,Phase 3,Phase 2 979-32-8
25 Dopamine agonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
26 Fertility Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Chorionic Gonadotropin Phase 4,Phase 2,Phase 3,Early Phase 1
29 Clomiphene Phase 4,Phase 2,Phase 3,Phase 1
30 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Contraceptive Agents Phase 4,Phase 3
32 Triptorelin Pamoate Phase 4,Phase 3,Phase 2
33 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
34 Hormones Phase 4,Phase 3,Phase 2,Phase 1
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
36 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37 Zuclomiphene Phase 4,Phase 2,Phase 3,Phase 1
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
39 Hypoglycemic Agents Phase 4
40 Pharmaceutical Solutions Phase 4,Phase 3
41 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2
42 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2
43 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1
44 Estrogens Phase 4,Phase 3,Phase 2,Phase 1
45 Polyestradiol phosphate Phase 4,Phase 3,Phase 2
46 Prolactin Release-Inhibiting Factors Phase 4,Phase 2,Phase 3
47 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
48 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2
49 Luteolytic Agents Phase 4,Phase 3
50 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 164)

# Name Status NCT ID Phase Drugs
1 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
2 Corifollitropin Alfa Application in PCOS Patients Unknown status NCT02215135 Phase 4 Corifollitropin alfa
3 Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist Unknown status NCT01347268 Phase 4
4 Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
5 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
6 Type of Gonadotropin and Embryo Kinetics of Development Unknown status NCT02402192 Phase 4 Corifollitropin alfa
7 Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders Unknown status NCT01926210 Phase 4
8 Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS Completed NCT02670304 Phase 4 letrozole;Aspirin
9 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Completed NCT01815138 Phase 4 hCG;hCG
10 The Use of GnRH Agonist Trigger in the Prevention of OHSS Completed NCT00349258 Phase 4 Leuprolide acetate
11 Endometrial Receptivity After GnRH Agonist Triggering Completed NCT01500863 Phase 4 hCG;triptorelin;Triptorelin, estradiol valerate, micronized vaginal progesterone;triptorelin, hCG;triptorelin, hCG;triptorelin, recombinant LH
12 Short Versus Long Protocol for IVF and IVF+ICSI Completed NCT00756028 Phase 4 Patients receiving short protocol IVF/ICSI-treatment.;Long protocol
13 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4 Menotropin;Progesterone vaginal insert;Follitropin beta;Progesterone in oil;leuprolide acetate
14 Endometrial Advancement After Rec or u-HCG Triggering Completed NCT00953628 Phase 4 10000 IU urinary HCG;250 mcg recombinant HCG
15 Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study Completed NCT01783301 Phase 4 FSH
16 The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation Completed NCT01065376 Phase 4
17 Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Completed NCT01233206 Phase 4 Metformin;Placebo administration
18 COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation Completed NCT02288143 Phase 4 COOL-COS
19 Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction Completed NCT01081626 Phase 4 Recombinant FSH (follitropin alpha)
20 Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles Completed NCT00627406 Phase 4 Buserelin and Pregnyl;Pregnyl;Buserelin and Pregnyl;Pregnyl
21 Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI Completed NCT03118830 Phase 4 Triptorelin;cetrorelix;Recombinant Follicle Stimulating Hormone
22 Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist Completed NCT01607203 Phase 4 Decapeptyl Daily;pregnyl
23 Menopur Mixed Protocol Completed NCT01417195 Phase 4 Bravelle;Menopur
24 MENOPUR® Versus FOLLISTIM® Completed NCT00802360 Phase 4 Menotropin;Progestrone vaginal insert;follitropin beta;Progesterone in oil;Ganirelix
25 Luteal Phase FSH in the IVF Poor Responder Completed NCT00225433 Phase 4 follitropin beta;ganirelix acetate
26 Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients Completed NCT02466204 Phase 4 corifollitropin alfa;Follitropin Beta
27 The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis Completed NCT01581359 Phase 4 Triptorelin acetate
28 Preventive Application of GnRH Antagonist on Early OHSS Recruiting NCT03188471 Phase 4 GnRH antagonist;aspirin
29 Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration Recruiting NCT02330770 Phase 4 GnRHa and HCG;GnRHa then HCG;GnRHa then HCG
30 Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer Recruiting NCT03309436 Phase 4 Clomiphene Citrate protocol
31 Efficacy and Safety of Medication Used to Stimulate Ovulation Recruiting NCT02715336 Phase 4 Ovulation induction with hCG and Lupron (GnRH agonist)
32 Follicular Steroid Genesis in Controlled Ovarian Stimulation Recruiting NCT02738580 Phase 4 COS with GnRH antagonists and rFSH;COS with GnRH antagonists and HP-HMG
33 Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS Recruiting NCT02436226 Phase 4 Clomiphene citrate and Human chorionic gonadotropin (HCG);Clomiphene citrate
34 Gonapure® in Multifollicular Stimulation in Egyptian Women Undergoing IVF/ICSI Recruiting NCT03057574 Phase 4 Follitropin Alfa
35 FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST) Active, not recruiting NCT01969201 Phase 4 Urofollitrophin;Follitrophin alpha
36 Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome? Terminated NCT01714648 Phase 4 Triptorelin 0.2 mg
37 Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF) Terminated NCT02221154 Phase 4
38 Low-dose Gonal-f® in Ovulation Induction Terminated NCT01871532 Phase 4 Gonal-f®
39 Metformin in Assisted Reproduction-MET-AR-study Terminated NCT00159575 Phase 4 Metformin / Placebo treatment for 4 months
40 Pituitary Down-regulation Before IVF for Women With Endometriosis Terminated NCT01757249 Phase 4 Combined Oral Contraceptive Pill (Microgynon 30)
41 Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles? Withdrawn NCT00804960 Phase 4 Letrozole;Std IVF Protocol
42 IVF Versus Gonadotropin Therapy in Women With CC Resistant PCOS Withdrawn NCT02458963 Phase 4 Gonadotropin
43 IVF Versus LOD in Women With CC Resistant PCOS Withdrawn NCT02456792 Phase 4
44 The Letrozole Administration During Luteal Phase Unknown status NCT02686151 Phase 3 Letrozole;Polygeline;Sodium Chloride;dexamethasone
45 GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles Unknown status NCT02262416 Phase 3 leuprolide
46 GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome Completed NCT01268761 Phase 3 GnRH antagonist (Cetrorelix);Placebo (saline solution)
47 Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome Completed NCT02290002 Phase 2, Phase 3 Calcium Dobesilate
48 Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome Completed NCT02271360 Phase 2, Phase 3 Calcium Dobesilate;Cabergoline
49 Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome Completed NCT02134249 Phase 2, Phase 3 Diosmin;Cabergoline
50 Calcium for Prevention of Ovarian Hyperstimulation Syndrome Completed NCT01427335 Phase 3 calcium;0.9 % saline

Search NIH Clinical Center for Ovarian Hyperstimulation Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: ovarian hyperstimulation syndrome

Genetic Tests for Ovarian Hyperstimulation Syndrome

Genetic tests related to Ovarian Hyperstimulation Syndrome:

# Genetic test Affiliating Genes
1 Ovarian Hyperstimulation Syndrome 28 FSHR

Anatomical Context for Ovarian Hyperstimulation Syndrome

MalaCards organs/tissues related to Ovarian Hyperstimulation Syndrome:

38
Ovary, Endothelial, Pituitary, Liver, Bone, Kidney, Thyroid

Publications for Ovarian Hyperstimulation Syndrome

Articles related to Ovarian Hyperstimulation Syndrome:

(show top 50) (show all 759)
# Title Authors Year
1
Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome. ( 29105961 )
2018
2
Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome. ( 29334275 )
2018
3
GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient? ( 29102428 )
2018
4
Ureteral obstruction and ruptured kidney following ovarian hyperstimulation syndrome. ( 29391290 )
2018
5
Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection. ( 29334199 )
2018
6
Severe ovarian hyperstimulation syndrome: Can we eliminate it through a multipronged approach? ( 29386731 )
2018
7
Clinical parameters of ovarian hyperstimulation syndrome (OHSS) following different hormonal triggers of oocyte maturation in IVF treatment. ( 29446481 )
2018
8
Severe ovarian hyperstimulation syndrome modifies early maternal serum beta-human chorionic gonadotropin kinetics, but obstetrical and neonatal outcomes are not impacted. ( 28911926 )
2017
9
Atypical case of preterm ovarian hyperstimulation syndrome. ( 28228430 )
2017
10
No-268-The Diagnosis and Management of Ovarian Hyperstimulation Syndrome. ( 29080733 )
2017
11
Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. ( 28535578 )
2017
12
A novel oocyte maturation trigger using 1500A IU of human chorionic gonadotropin plus 450A IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. ( 29086322 )
2017
13
Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome. ( 27771155 )
2017
14
Ovarian hyperstimulation syndrome following GnRH agonist trigger-think ectopic. ( 28600619 )
2017
15
Ovarian hyperstimulation syndrome as a rare cause of acute bilateral limb and renal ischemia. ( 29349392 )
2017
16
Reduced Intellectual Ability in Offspring of Ovarian Hyperstimulation Syndrome: A Cohort Study. ( 28532740 )
2017
17
Management of ovarian hyperstimulation syndrome with abdominal compartment syndrome, based on intravesical pressure measurement. ( 29259454 )
2017
18
A review on ovarian hyperstimulation syndrome (OHSS) management strategies. ( 28322539 )
2017
19
Methylprednisolone for prevention of ovarian hyperstimulation syndrome in patients with polycystic ovarian syndrome undergoing in-vitro fertilisation: a randomised controlled trial. ( 28903582 )
2017
20
Outpatient management of severe ovarian hyperstimulation syndrome: a systematic review and a review of existing guidelines. ( 28554223 )
2017
21
Ovarian torsion and spontaneous ovarian hyperstimulation syndrome in a twin pregnancy: A case report. ( 28371633 )
2017
22
Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney. ( 28440686 )
2017
23
Life-threatening Medical Complications Due to Ovarian Hyperstimulation Syndrome: A Hidden Etiology. ( 29322719 )
2017
24
Long hospitalization for severe ovarian hyperstimulation syndrome with persistent right hydrothorax and two occurrences of pneumonia. ( 28099716 )
2017
25
Early hCG administration as an alternative prevention strategy of ovarian hyperstimulation syndrome during an IVF cycle. ( 28150929 )
2017
26
Gonadotropin-Releasing Hormone-Agonist Triggering and a Freeze-All Approach: The Final Step in Eliminating Ovarian Hyperstimulation Syndrome? ( 28558117 )
2017
27
Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome ( 29120551 )
2017
28
Ovarian hyperstimulation syndrome due to follicle-stimulating hormone-secreting pituitary adenomas. ( 28676954 )
2017
29
First mutation in the FSHR cytoplasmic tail identified in a non-pregnant woman with spontaneous ovarian hyperstimulation syndrome. ( 28446136 )
2017
30
Prevention and management of ovarian hyperstimulation syndrome. ( 28262238 )
2017
31
In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome (OHSS). ( 28379469 )
2017
32
The Clinical Characteristics of Acute Cerebrovascular Accidents Resulting from Ovarian Hyperstimulation Syndrome. ( 28253509 )
2017
33
Zinc finger gene 217 (ZNF217) Promoted Ovarian Hyperstimulation Syndrome (OHSS) through Regulating E2 Synthesis and Inhibiting Thrombospondin-1 (TSP-1). ( 28607476 )
2017
34
Correction to: Irani etA al., Unilateral pleural effusion as the sole clinical presentation of severe ovarian hyperstimulation syndrome: a systematic review. ( 29140149 )
2017
35
What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study. ( 28710674 )
2017
36
Cesarean Delivery in a Case of Persistent Second Trimester Ovarian Hyperstimulation Syndrome. ( 29073689 )
2017
37
Author Correction: A novel oocyte maturation trigger using 1500A IU of human chorionic gonadotropin plus 450A IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. ( 29178020 )
2017
38
A New Perspective on the Risk of Hypercoagulopathy in Ovarian Hyperstimulation Syndrome Using Thromboelastography. ( 28299993 )
2017
39
Two cases of first onset intrahepatic cholestasis of pregnancy associated with moderate ovarian hyperstimulation syndrome after IVF treatment and review of the literature. ( 28319428 )
2017
40
Large-Volume Paracentesis, up to 27 L, With Adjuvant Vaginal Cabergoline in the Case of Severe Ovarian Hyperstimulation Syndrome with Successful Pregnancy Outcome: A Case Report. ( 29142455 )
2017
41
Sliding scale HCG trigger yields equivalent pregnancy outcomes and reduces ovarian hyperstimulation syndrome: Analysis of 10,427 IVF-ICSI cycles. ( 28441461 )
2017
42
The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome. ( 28795043 )
2017
43
Elective frozen-thawed embryo transfer (FET) in women at risk for ovarian hyperstimulation syndrome. ( 29279182 )
2017
44
A proteomic analysis identifies candidate early biomarkers to predict ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients. ( 28534980 )
2017
45
Sequential E2 levels not ovarian maximal diameter estimates were correlated with outcome of cetrotide therapy for management of women at high-risk of ovarian hyperstimulation syndrome: a randomized controlled study. ( 29132339 )
2017
46
GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome. ( 28706366 )
2017
47
Association of -460C/T and +405 G/C polymorphisms of vascular endothelial growth factor gene and susceptibility to ovarian hyperstimulation syndrome. ( 28462400 )
2017
48
Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. ( 28403961 )
2017
49
A Case with Severe Endometriosis, Ovarian Hyperstimulation Syndrome, and Isolated Unilateral Pleural Effusion after IVF. ( 28770117 )
2017
50
A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. ( 28854728 )
2017

Variations for Ovarian Hyperstimulation Syndrome

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Hyperstimulation Syndrome:

71
# Symbol AA change Variation ID SNP ID
1 FSHR p.Thr449Ile VAR_017244 rs28928870
2 FSHR p.Asp567Asn VAR_017245 rs28928871
3 FSHR p.Ser128Tyr VAR_039279
4 FSHR p.Thr449Ala VAR_039282
5 FSHR p.Ile545Thr VAR_039284
6 FSHR p.Met512Ile VAR_074535
7 FSHR p.Val514Ala VAR_074536
8 FSHR p.Ala575Val VAR_074537

ClinVar genetic disease variations for Ovarian Hyperstimulation Syndrome:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 FSHR NM_000145.3(FSHR): c.919G> A (p.Ala307Thr) single nucleotide variant drug response rs6165 GRCh37 Chromosome 2, 49191041: 49191041
2 FSHR NM_000145.3(FSHR): c.2039G> A (p.Ser680Asn) single nucleotide variant drug response,risk factor rs6166 GRCh37 Chromosome 2, 49189921: 49189921
3 FSHR NM_000145.3(FSHR): c.1346C> T (p.Thr449Ile) single nucleotide variant Pathogenic rs28928870 GRCh37 Chromosome 2, 49190614: 49190614
4 FSHR NM_000145.3(FSHR): c.1699G> A (p.Asp567Asn) single nucleotide variant Pathogenic rs28928871 GRCh37 Chromosome 2, 49190261: 49190261
5 FSHR NM_000145.3(FSHR): c.1345A> G (p.Thr449Ala) single nucleotide variant Pathogenic rs121909663 GRCh37 Chromosome 2, 49190615: 49190615
6 FSHR NM_000145.3(FSHR): c.1634T> C (p.Ile545Thr) single nucleotide variant Pathogenic rs121909664 GRCh37 Chromosome 2, 49190326: 49190326
7 FSHR NM_000145.3(FSHR): c.383C> A (p.Ser128Tyr) single nucleotide variant Pathogenic rs121909665 GRCh37 Chromosome 2, 49217768: 49217768

Expression for Ovarian Hyperstimulation Syndrome

Search GEO for disease gene expression data for Ovarian Hyperstimulation Syndrome.

Pathways for Ovarian Hyperstimulation Syndrome

Pathways related to Ovarian Hyperstimulation Syndrome according to KEGG:

36
# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080

GO Terms for Ovarian Hyperstimulation Syndrome

Cellular components related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 ALB AMH F5 GNRH1 REN VEGFA
2 extracellular region GO:0005576 9.23 ALB AMH CGA F5 GNRH1 KDR
3 platelet alpha granule lumen GO:0031093 9.13 ALB F5 VEGFA

Biological processes related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.87 ALB GNRH1 KDR VEGFA
2 regulation of receptor activity GO:0010469 9.83 AMH CGA GNRH1 VEGFA
3 positive regulation of cell migration GO:0030335 9.75 CGA KDR VEGFA
4 platelet degranulation GO:0002576 9.69 ALB F5 VEGFA
5 male gonad development GO:0008584 9.61 FSHR LHCGR REN
6 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.56 KDR VEGFA
7 female gonad development GO:0008585 9.55 CYP19A1 FSHR
8 positive regulation of focal adhesion assembly GO:0051894 9.54 KDR VEGFA
9 uterus development GO:0060065 9.49 CYP19A1 FSHR
10 regulation of osteoclast differentiation GO:0045670 9.48 FSHR LHCGR
11 cell migration involved in sprouting angiogenesis GO:0002042 9.46 KDR VEGFA
12 positive regulation of positive chemotaxis GO:0050927 9.4 KDR VEGFA
13 positive regulation of adenylate cyclase activity GO:0045762 9.37 FSHR LHCGR
14 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.32 KDR VEGFA
15 follicle-stimulating hormone signaling pathway GO:0042699 9.26 FSHR LHCGR
16 primary ovarian follicle growth GO:0001545 9.16 FSHR LHCGR
17 hormone-mediated signaling pathway GO:0009755 9.13 FSHR LHCGR REN
18 gonad development GO:0008406 8.8 AMH CGA FSHR

Molecular functions related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.33 AMH CGA GNRH1
2 G-protein coupled peptide receptor activity GO:0008528 9.26 FSHR LHCGR
3 protein-hormone receptor activity GO:0016500 8.96 FSHR LHCGR
4 follicle-stimulating hormone receptor activity GO:0004963 8.62 FSHR LHCGR

Sources for Ovarian Hyperstimulation Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....